acute myeloid leukemia
Interviews and expert commentary tagged “acute myeloid leukemia” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Amir Fathi MD; ASH 2025: Paradigm Study Finds Young, Fit Adults with Acute Myeloid Leukemia Do Better with Gentler Azacitidine/Venetoclax Initial Therapy
An interview with Amir Fathi MD from Massachusetts General Hospital discusses the Paradigm study presented at ASH 2025. The phase two randomized trial found that young, fit adults with acute myeloid leukemia had improved event-free survival and higher response rates with azacitidine/venetoclax initial therapy. This gentler treatment also led to fewer toxicities and better quality of life compared to standard induction chemotherapy.
Jesse Tettero MD PhD; ASH 2025: Measurable Residual Disease Can Predict Overall Survival in Patients with Acute Myeloid Leukemia
Dr. Jesse Tettero discusses findings from the HARMONY Alliance study, presented at ASH 2025, validating measurable residual disease (MRD) as a robust predictor of overall survival in acute myeloid leukemia (AML) patients. The study supports MRD's potential as a regulatory surrogate endpoint, particularly MFC-MRD in non-transplanted patients, to accelerate drug development. This large pooled analysis provides critical evidence for future AML drug approvals.
Single-cell RNA Sequencing Provides Comprehensive Map of Acute Myeloid Leukemia Cell States
Andy Zeng, Toronto: Transcriptome Map Key to Malignant Transformation in AML
Genomic-led AML Clinical Decision Making Within Seven Days
The “Beat AML” study assesses an algorithm screening for genomic features in order to choose appropriate targeted therapies for individual patients with their specific form of AML